Cardiac

Cardiac biomarkers are substances released into the blood as the by-product of injury to the heart or vascular system. Measurement of these biomarkers is used to help diagnose, evaluate, and monitor patients in a variety of settings ranging from emergency rooms to cardiology offices. Currently, only a few cardiac biomarker diagnostic tests are used by physicians for routine diagnosis. However in recent years, biomarkers are finding new markets as predictive or preventive medicine markers, and point-of-care solutions are particularly important.

LabNow and the McDevitt Laboratory are participating in a nationwide multi-million dollar program sponsored by the National Institute of Dental and Craniofacial Research division at the National Institutes of Health. This program has led to the development of a series of cardiac biomarker tests, using both saliva and serum specimens, amenable for adaptation into the LabNow platform. To date, 32 biomarkers have been chosen for further focused activities in three areas of interest:

• Classification of coronary artery disease (Risk Assessment)
• Diagnosis of acute myocardial infarction (AMI Diagnosis)
• Assessment of recurrent AMI (Prognosis)

LabNow is actively seeking development partnerships to commercialize a host of cardiac diagnostic markers for the indications described above.

Learn more about the cancer research at the McDevitt Research Laboratory.